Literature DB >> 28672949

Long-term adefovir therapy may induce Fanconi syndrome: A report of four cases.

Fan Pan1, Yingchao Wang2,3, Xin Zhang4, Qingfeng Lin4, Xiaolong Liu2,3, Yi Jiang1, Chen Pan4.   

Abstract

Fanconi syndrome is a rare disease characterized by dysfunction of the proximal renal tubules as a result of various pathogenic events. Drug-induced Fanconi syndrome may be neglected or misdiagnosed, which increases the level of suffering. The aim of the present study was to conduct an investigation into the effects of adefovir (ADV)-induced Fanconi syndrome. Four typical cases of Fanconi syndrome caused by long-term ADV therapy (2-9 years) were diagnosed at our hospital. A complete medical and therapy history was collected from all four patients prior to a physical examination. Laboratory and diagnostic examinations were also conducted. Following this, the patients were diagnosed and a treatment regimen was decided upon. Outcomes of the treatment regimen were observed. Common manifestations of all the four patients were: Renal tubular reabsorption dysfunction; imbalanced electrolyte acid-base ratio; elevated cystatin C levels; severe hypophosphatemia and diffused systemic pain; osteoporosis; and difficultly walking. When ADV was replaced with supportive treatment, all the four patients exhibited symptom relief. These findings indicate that long-term ADV therapy may induce Fanconi syndrome. For patients with a history of such therapy, the possibility of Fanconi syndrome should be assessed and monitored closely for indicators, including altered glomerular and renal tubular function. Once diagnosed, the agent should be immediately discontinued and prompt symptomatic treatment should be administered.

Entities:  

Keywords:  Fanconi syndrome; adefovir; antiviral therapy; chronic hepatitis B virus; electrolyte disturbances; kidney damage; osteoporosis

Year:  2017        PMID: 28672949      PMCID: PMC5488596          DOI: 10.3892/etm.2017.4483

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  15 in total

Review 1.  Using phosphate supplementation to reverse hypophosphatemia and phosphate depletion in neurological disease and disturbance.

Authors:  Lena Håglin
Journal:  Nutr Neurosci       Date:  2015-04-24       Impact factor: 4.994

Review 2.  Drug safety evaluation of adefovir in HBV infection.

Authors:  Mauro Viganò; Pietro Lampertico; Massimo Colombo
Journal:  Expert Opin Drug Saf       Date:  2011-06-15       Impact factor: 4.250

3.  Clinical problem-solving. Wasting away.

Authors:  Ole-Petter R Hamnvik; Carolyn B Becker; Bruce D Levy; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

4.  Editor's Highlight: Comparative Renal Safety Assessment of the Hepatitis B Drugs, Adefovir, Tenofovir, Telbivudine and Entecavir in Rats.

Authors:  Marianne Uteng; Andreas Mahl; Nicolau Beckmann; Alessandro Piaia; David Ledieu; Valerie Dubost; Elaine Tritto; Armin Wolf; Pierre Moulin; Li Li; Salah-Dine Chibout; Francois Pognan
Journal:  Toxicol Sci       Date:  2016-10-13       Impact factor: 4.849

Review 5.  Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes.

Authors:  Hairong Zhu; Jian Wu; Xizhong Shen
Journal:  Scand J Gastroenterol       Date:  2016-10-31       Impact factor: 2.423

Review 6.  [Calcium pros and cons significance and risk of phosphorus supplementation. The necessity of phosphorus supplementation for hypophosphatemia].

Authors:  Eiji Takeda
Journal:  Clin Calcium       Date:  2011-12

7.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Carol L Brosgart; Katyna Borroto-Esoda; Sarah Arterburn; Steven L Chuck
Journal:  Gastroenterology       Date:  2006-09-20       Impact factor: 22.682

Review 8.  Magnesium and phosphorus.

Authors:  J R Weisinger; E Bellorín-Font
Journal:  Lancet       Date:  1998-08-01       Impact factor: 79.321

9.  Side effects of long-term oral antiviral therapy for hepatitis B.

Authors:  Robert J Fontana
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 10.  Drug-induced Fanconi's syndrome.

Authors:  Hassane Izzedine; Vincent Launay-Vacher; Corinne Isnard-Bagnis; Gilbert Deray
Journal:  Am J Kidney Dis       Date:  2003-02       Impact factor: 8.860

View more
  1 in total

1.  Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm.

Authors:  Alvin Lee Day; Sarah L Morgan; Kenneth G Saag
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-06-15       Impact factor: 5.346

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.